PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 13 | 2 (47) | 77-83
Article title

Zastosowanie laktoferryny w profilaktyce i leczeniu zaburzeń metabolicznych

Content
Title variants
EN
The use of lactoferrin in the prevention and treatment of metabolic disorders
Languages of publication
PL
Abstracts
EN
Nowadays, the metabolic syndrome is more frequently diagnosed among children and adolescents due to the growing epidemic of obesity. Therefore, studies are being conducted on the effects of substances of natural origin that could have a supporting effect as for the reduction of the adipose tissue. One of them is lactoferrin (LF) – an iron binding glycoprotein, produced by glandular epithelial cells and neutrophils. It is present in all secretions, but the highest concentration of LF can be found in mammals’ milk. LF receptors are localized on variety of cells such as monocytes, lymphocytes, adipocytes, hepatocytes and endothelial cells. So far its multidirectional actions such as: anti-inflammatory, antibacterial, antiviral, mmunomodulatory, antioxidant and anticancer have been widely known, but not much has been noted concerning the influence of the protein on lipid and carbohydrate homeostasis. The paper presents an overview of the research and clinical observations, with people’s participation, on the possible effects of LF in the view of beneficial influence on the disorders which are the elements of metabolic syndrome, with reference to selected actions of LF described in animal investigations or in vitro tests. Due to the complex and beneficial effects on lipid and carbohydrate homeostasis parameters, studies on its practical use are still in progress. Pediatr. Endocrinol. 13/2014;2(47):77-84.
PL
Zespół metaboliczny jest coraz częściej rozpoznawany w populacji dzieci i młodzieży, co wiąże się ze wzrastającą epidemią otyłości. Dlatego też trwają badania nad działaniem naturalnie występujących substancji, które mogłyby mieć wspomagający efekt w walce z nadmiarem tkanki tłuszczowej. Jedną z nich jest laktoferryna (LF) – glikoproteina wiążąca żelazo, produkowana przez komórki gruczołowe nabłonka oraz przez granulocyty obojętnochłonne. Obecna jest we wszystkich wydzielinach, a w największym stężeniu występuje w mleku ssaków. Jej receptory zlokalizowane są na różnorodnych komórkach, w tym monocytach, limfocytach, adipocytach, hepatocytach i komórkach śródbłonka. Dotychczas poznano jej wielokierunkowe działanie: przeciwzapalne, przeciwbakteryjne, przeciwwirusowe, immunomodulujące, przeciwutleniające i przeciwnowotworowe, natomiast mniej znany jest wpływ tego białka na gospodarkę lipidową i weglowodanową. Niniejsza praca prezentuje przegląd badań i obserwacji klinicznych z udziałem ludzi nad możliwymi efektami działania tego białka w perspektywie korzystnego wpływu na zaburzenia będące elementami zespołu metabolicznego, z odwołaniem do wybranych mechanizmów działania LF, opisanych dzięki doświadczeniom in vitro bądź na zwierzętach. Ze względu na złożony i korzystny wpływ omawianego białka na parametry gospodarki lipidowej i węglowodanowej stale trwają prace nad jego praktycznym zastosowaniem. Endokrynol. Ped. 13/2014;2(47):77-84.
Discipline
Publisher
Year
Volume
13
Issue
Pages
77-83
Physical description
Dates
published
2014
References
  • [1] International DiabetesFederation: Consensus Worldwide Definition of the Metabolic Syndrome. http://www.idf.org/webdata/ docs/IDF_Meta_def_final.pdf (10.03.2014)
  • [2] International DiabetesFederation: IDF consensus definition of metabolic syndrome in children and adolescents. http://www. idf.org/webdata/docs/Mets_definition_children.pdf (10.03.2014)
  • [3] Kułaga Z., Litwin M., Tkaczyk M. et al.: Polish 2010 growth references for school-aged children and adolescents. Eur. J. Pe- diatr.,2011:170(5), 599-609.
  • [4] Baker E.N.., Baker H.M.: Molecular structure, binding properties and dynamics of lactoferrin. Cell. Mol. Life. Sci., 2005:62, 2531- 2539.
  • [5] Ward P.P., Paz E., Conneely O.M.: Multifunctional roles of lactoferrin: a critical overview. Cell. Mol. Life. Sci., 2005:62, 2540-2548.
  • [6] Kimoto H.: Case report of 4 patients on the improvement of serum lipids by enteric-coated LF tablets. Progr. Medicine, 2003:23, 1519-1523.
  • [7] Shimizu H.: Development of an enteric-coated lactoferrin tablet and its application. Biometals, 2004:17(3), 343-347.
  • [8] Ono T., Murakoshi M., Suzuki N. et al.: Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accu- mulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br. J. Nutr., 2010:104(11), 1688-1695.
  • [9] Yagi M., Suzuki N., Takayama T. et al.: Lactoferrin suppress the adipogenic differentiation of MC3T3-G2/PA6 cells. J. Oral Sci., 2008:50(4), 419-425.
  • [10] Ono T., Morishita S., Fujisaki C. et al.: Effects of pepsin and trypsin on the anti-adipogenic action of lactoferrin against pre-ad- ipocytes derived from rat mesenteric fat. Br. J. Nutr., 2011:105(2), 200-211.
  • [11] Moreno-Navarrete J.M., Ortega F.J., Bassols J. et al.: Decreased circulating lactoferrin in insulin resistance and altered glu- cose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J. Clin. Endocrinol. Metab., 2009:94(10), 4036-4044.
  • [12] Moreno-Navarrete J.M., Ortega F.J., Bassols J. et al.: Association of circulating lactoferrin concentration and 2 nonsynony- mous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clin. Chem., 2008:54(2), 301-309.
  • [13] Willnow T.E., Goldstein J.L., Orth K.J. et al.: Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. Biol. Chem., 1992:267(36), 26172-26180.
  • [14] Kajikawa M., Ohta T., Takase M. et al.: Lactoferrin inhibits cholesterol accumulation in macrophages mediated by acetylated or oxidized low-density lipoproteins. Biochim. Biophys. Acta, 1994:1213(1), 82-90.
  • [15] Fernández-Real J.M., García-Fuentes E., Moreno-Navarrete J.M.: Fat overload induces changes in circulating lactoferrin that are associated with postprandial lipemia and oxidative stress in severely obese subjects. Obesity (Silver Spring), 2010:18(3), 482-488.
  • [16] Baumrucker C.R., Erondu N.E.: Insulin-like growth factor (IGF) system in the bovine mammary gland and milk. J. Mammary Gland Biol. Neoplasia, 2000:5(1), 53-64. Review.
  • [17] Vassiliou G., Benoist F., Lau P. et al.: The low density lipoprotein receptor-related protein contributes to selective uptake of high density lipoprotein cholesteryl esters by SW872 liposarcoma cells and primary human adipocytes. J. Biol. Chem., 2001:276(52), 48823-48830.
  • [18] Kim J., Ko Y., Park Y.K. et al.: Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris. Nutrition, 2010:26(9), 902-909.
  • [19] Lyons T.E., Miller M.S., Serena T. et al.: Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am. J. Surg., 2007:193(1), 49-54.
  • [20] Ricci-Cabello I., Herrera M.O., Artacho R.: Possible role of milk-derived bioactive peptides in the treatment and prevention of metabolic syndrome. Nutr. Rev., 2012:70(4), 241-255.
  • [21] Pal S., Radavelli-Bagatini S.:The effects of whey protein on cardiometabolic risk factors. Obes. Rev., 2013:14(4), 324-343.
  • [22] Krissansen G.W.: Emerging health properties of whey proteins and their clinical implications. J. Am. Coll. Nutr., 2007:26(6), 713S-723S.
  • [23] Artym J.: Laktoferyna w szklance mleka. W: Laktoferyna – niezwykłe białko., Borgis, Warszawa 2013, 197-200.
  • [24] Italian Task Force for the Study and Prevention of Neonatal Fungal Infections–the Italian Society of Neonatology. Manzoni P., StolfiI., MessnerH. et al.: Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics, 2012:129(1), 116-123.
  • [25] CFSAN/Office of Food Additive Safety: Agency response letter: GRAS notice No. GRN 000077. U. S. Food and Drug Administration Web site. http://www.fda.gov/food/ingredientspackaginglabeling/gras/noticeinventory/ucm154188.htm (20.02.2014)
  • [26] EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA): Scientific opinion on bovine lactoferrin. EFSA J., 2012:10, 2701.
  • [27] Sherman M.P.: New concepts of microbial translocation in the neonatal intestine: mechanisms and prevention. Clin. Perinatol., 2010:37(3), 565-579.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-1730-0282-1488
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.